Intrinsiqq
Nephros Inc. logo

Nephros Inc.

NEPH

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$33M
EPS$0.18
P/E16.83
P/FCF–
EV/EBITDA14.84
FCF Yield–
Div. Yield–
Net Debt/FCF–
Nephros Inc. intrinsic value
52-Week Range
$2.78$5.79

Profitability & Returns

Revenue (TTM)

$22M

▲ +32.7% YoY

Net Income (TTM)

$2M

▲ +1513.5% YoY

Op. Margin

8.48%

▲ +6.1pp YoY

ROIC

14.80%

▲ +10.6pp YoY

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

-$910K

▲ +434.3% YoY

Net Debt

-$4M

Net Cash Position

Cash & Equiv.

$5M

5Y CAGR: +17.0%

Continue Research

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with NEPH

CompareIntrinsic value
DRIODarioHealth Corp.
$1.26-23.64%25
VVOSVivos Therapeutics, Inc.
$0.10+2.08%26
SNOASonoma Pharmaceuticals Inc.
$1.09-6.84%40
PROFProfound Medical Corp.
$7.42-0.27%50
SRTSSensus Healthcare Inc.
$2.33-27.80%18
BTCYBiotricity Inc.
$0.06+5.41%64
DYNTQDynatronics Corp
$0.00+0.00%29
MDAISpectral AI Inc.
$1.30-3.70%10

Nephros (NEPH) in four numbers

Fair value (earnings)
$2.90
Price $3.05 is 5% above it.
Intrinsic Value
Quality score
55/100
Best check: revenue growth, 21.3%. Weakest: share count change, 8.8%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
16.83
From the last twelve months of earnings.
Financials

Questions about Nephros

Is Nephros (NEPH) overvalued?

At $3.05, Nephros' price is 5% above the $2.90 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 16.83 times earnings. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Nephros' fair value?

Intrinsiqq's calculator puts Nephros' fair value at $2.90 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 24.3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $2.18. Every input can be changed on the Intrinsic Value tab.

Is Nephros a high-quality business?

Nephros scores 55 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 21.3%, and its weakest is share count change at 8.8%. The Quality tab shows every check against its target.

Does Nephros (NEPH) pay a dividend?

No. Nephros (NEPH) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in NEPH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NEPH

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.